TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS DUE TO ADVANCED LUNG CANCER BY TRANSFER OF AUTOLOGOUS LAK CELLS COMBINED WITH rIL-2 OR rIL-2 ALONE

Experimental study both in vitro and in vivotogether with clinical trials showed that LAKcells have antitumor and antimetastatic effects(1-5)and that these effects are closely related tothe number of LAK cells transferred and the ad-ministration of rIL-2(1,6-8).Usually,autologousPBL’s are used as the source of LAK precursorsin the adoptive immunotherapy of cancer patients.But this not only puts an added burden on thecancer patient,it can cause serious side effectsas well(9).Although TIL’s may provide a solu-tion to this problem(10,11),their isolation fromsolid tumors is complex and consumes many rea-gents.We have reported that the isolation oflymphocytes from malignant ascites or from ma-lignant pleural effusions is not only simple

Th-LAK细胞杀伤肿瘤细胞的活性及其机理的研究

在体外观察了用rIL－2激活的人胎胸腺细胞（Th－LAK细胞），对K562癌细胞（以下称靶细胞）的杀伤过程、在倒置显微镜下，可见Th－LAK细胞呈花环状围绕靶细胞，继而靶细胞内出现颗粒，后被破坏。在扫描电镜下，Th-LAK细胞和靶细胞先互相接触．然后细胞胞浆互相融合，4h时靶细胞核膜出现孔洞，微绒毛消失，靶细胞逐渐破裂死亡。在透射电镜下Th－LAK细胞和靶细胞混合培养30min后，就可见ThLAK细胞胞浆绒毛伸向靶细胞，互相融合，染色体浓缩，溶酶体可见，细胞膜不完整，形成凋落小体以至碎裂死亡。部分Th-LAK细胞中发现微管泡结构。